Abstract

The efficacy of copper aspirinate against thrombotic diseases has been tested
in animal models. The results show that copper aspirinate, following ig pretreatment
for 7 days at 0.012mmol/kg markedly prolonged the bleeding time and inhibited the
mortality induced by arachidonic acid (AA) in mice. On cereral ischemia model
pretreatment with 0.018mmol/kg copper aspirinate ig significantly increased
survival of animals and the density of intact hippocampal CA1 cells and decreased
brain calcium concentration. Its anticerebral ischemia activity was superior to or
equal to nimodipine. It is, therefore, suggested that copper aspirinate is very promising
in becoming an antithrombotic drug in preventing and treating thrombotic diseases.